in  Show more search options Additional Search Options
 
  • 350 leading medical journals
  • 28 specialties covered
  • Ranked, rated and reviewed by experts
  • Delivered on your terms
Subscribe

Delayed Remission after Transsphenoidal Surgery in Patients with Cushing's Disease
Valassi, E..., Biller, B...M...K..., Swearingen, B... | J Clin Endocrinol Metab | vol. 95, 601 - 610, 2010

To view our Expert Rating and Evidence Rank Login or Subscribe Read the Article Rate this Article

SUBJECT Endocrinology  >  Neuroendocrinology

Abstract

Background: 

Transsphenoidal surgery (TSS) is the treatment of choice for Cushing's disease (CD). Postoperative hypercortisolemia mandates further therapy.

Objective: 

The aim of the study was to characterize patients without immediate postoperative remission who have a delayed decrease to normal or low cortisol levels without further therapy.

Design and Setting: 

A retrospective case series was conducted at three tertiary care centers.

Patients and Intervention: 

We reviewed the records of 620 patients (512 females, 108 males; mean age, 38±13yr) who underwent transsphenoidal pituitary surgery for CD between 1982 and 2007.

Results: 

Outcomes were classified into the following three groups based upon the postoperative pattern of cortisol testing: group IC (immediate control) included 437 of the 620 patients (70.5%) with hypocortisolism and/or cortisol normalization throughout the postoperative follow-up; group NC (no control) included 148 of 620 patients (23.9%) with persistent hypercortisolism; and group DC (delayed control) included 35 of 620 patients (5.6%)who had early elevated or normal UFC levels and developed a delayed and persistent cortisol decrease after an average of 38±50 postoperative days. The total rate of recurrence was 13% at a median follow-up time of 66 months after TSS; the cumulative rate of recurrence at 4.5yr was significantly higher in group DC vs. group IC (43 vs. 14%; P=0.02).

Conclusions: 

Hormonal assessment in the immediate postoperative period after TSS for CD may be misleading because delayed remission can occur in a subset of patients. Expectant management and retesting may spare some patients from unnecessary further treatment. Optimal timing to determine the need for further therapy after TSS remains to be determined.

Meet the Expert:
William H. Ludlam, MD
Director, Seattle Pituitary Center
Neuroscience Institute, Swedish Medical Center

To view Expert Rating
Login or Subscribe

Home    Browse    Search    My Profile    My Alerts Top of page

Registered User Agreement  |  Contact Us  |  Privacy Policy  |  Terms and Conditions

Copyright © 2007, Elsevier Inc . All rights reserved.

Other web sites from Elsevier Health:
iConsult: Clinical Decision Support | ProceduresConsult | Expert Consult | Student Consult | Path Consult
USMLE Consult | The Clinics | OncologySTAT | The Lancet | ElsevierHealth.com | ElsevierHealthCareers.com
Imaging Consult

An Elsevier Product